摘要
目的:研究非小细胞肺癌(NSCLC)及肺部良性疾病患者血清癌胚抗原(CEA)、细胞角蛋白质19片段(CYFRA21-1)和SCC的水平,探讨联合检测在诊断中的价值。方法:检测70例NSCLC患者和20例良性肺疾病患者血清中CEA、CYFRA21-1和SCC的水平。结果:NSCLC组血清CEA、CYFRA21-1和SCC的测定值均高于肺良性病变组(P<0.05),并且与病理类型有关。CEA的血清浓度水平与肿瘤的分期有关。三项肿瘤标记物联合检测的敏感性为87.1%,优于单项检测。结论:CEA、CYFRA21-1和SCC的联合检测可以提高对NSCLC的诊断水平,有助于对病情和预后的判断。
Objetive To study the level of serum CEA、CYFRA21-1 and SCC in non-small cell lung cancer(NSCLC)patients and to evaluate the clinical diagnostic value of combined detection of them.Methods CEA、CYFRA21-1 and SCC were detected in 70 patients with NSCLC and 20 patients with benign lung disease.Results The serum levels of CEA、CYFRA21-1 and SCC in patients with lung cancer were significant higher than those with benign lung disease(P<0.05),and were related to pathology type.The serum level of CEA was related t...
出处
《实用医技杂志》
2007年第15期1966-1968,共3页
Journal of Practical Medical Techniques